Suppr超能文献

单纯疱疹病毒对早期抗病毒反应的逃避

Evasion of early antiviral responses by herpes simplex viruses.

作者信息

Suazo Paula A, Ibañez Francisco J, Retamal-Díaz Angello R, Paz-Fiblas Marysol V, Bueno Susan M, Kalergis Alexis M, González Pablo A

机构信息

Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, 8331010 Santiago, Chile.

Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, 8331010 Santiago, Chile ; INSERM UMR1064, 44093 Nantes, France.

出版信息

Mediators Inflamm. 2015;2015:593757. doi: 10.1155/2015/593757. Epub 2015 Mar 30.

Abstract

Besides overcoming physical constraints, such as extreme temperatures, reduced humidity, elevated pressure, and natural predators, human pathogens further need to overcome an arsenal of antimicrobial components evolved by the host to limit infection, replication and optimally, reinfection. Herpes simplex virus-1 (HSV-1) and herpes simplex virus-2 (HSV-2) infect humans at a high frequency and persist within the host for life by establishing latency in neurons. To gain access to these cells, herpes simplex viruses (HSVs) must replicate and block immediate host antiviral responses elicited by epithelial cells and innate immune components early after infection. During these processes, infected and noninfected neighboring cells, as well as tissue-resident and patrolling immune cells, will sense viral components and cell-associated danger signals and secrete soluble mediators. While type-I interferons aim at limiting virus spread, cytokines and chemokines will modulate resident and incoming immune cells. In this paper, we discuss recent findings relative to the early steps taking place during HSV infection and replication. Further, we discuss how HSVs evade detection by host cells and the molecular mechanisms evolved by these viruses to circumvent early antiviral mechanisms, ultimately leading to neuron infection and the establishment of latency.

摘要

除了要克服诸如极端温度、低湿度、高压和天敌等物理限制外,人类病原体还需要克服宿主进化出的一系列抗菌成分,以限制感染、复制,并在最佳情况下防止再次感染。单纯疱疹病毒1型(HSV-1)和单纯疱疹病毒2型(HSV-2)感染人类的频率很高,并通过在神经元中建立潜伏感染而在宿主体内终生持续存在。为了进入这些细胞,单纯疱疹病毒(HSV)必须进行复制,并在感染后早期阻断上皮细胞和先天免疫成分引发的宿主即时抗病毒反应。在这些过程中,受感染和未受感染的邻近细胞,以及组织驻留和巡逻免疫细胞,将感知病毒成分和细胞相关的危险信号并分泌可溶性介质。I型干扰素旨在限制病毒传播,而细胞因子和趋化因子则会调节驻留和进入的免疫细胞。在本文中,我们讨论了与HSV感染和复制早期步骤相关的最新发现。此外,我们还讨论了HSV如何逃避宿主细胞的检测,以及这些病毒为规避早期抗病毒机制而进化出的分子机制,最终导致神经元感染和潜伏感染的建立。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0181/4396904/fc9a1c69263a/MI2015-593757.001.jpg

相似文献

1
Evasion of early antiviral responses by herpes simplex viruses.
Mediators Inflamm. 2015;2015:593757. doi: 10.1155/2015/593757. Epub 2015 Mar 30.
2
Mechanisms employed by herpes simplex virus 1 to inhibit the interferon response.
J Interferon Cytokine Res. 2009 Sep;29(9):599-607. doi: 10.1089/jir.2009.0074.
3
Herpes Simplex Virus Type 1 Interactions with the Interferon System.
Int J Mol Sci. 2020 Jul 21;21(14):5150. doi: 10.3390/ijms21145150.
5
Evasion of host antiviral innate immunity by HSV-1, an update.
Virol J. 2016 Mar 8;13:38. doi: 10.1186/s12985-016-0495-5.
6
The Race between Host Antiviral Innate Immunity and the Immune Evasion Strategies of Herpes Simplex Virus 1.
Microbiol Mol Biol Rev. 2020 Sep 30;84(4). doi: 10.1128/MMBR.00099-20. Print 2020 Nov 18.
7
Herpes simplex virus interference with immunity: Focus on dendritic cells.
Virulence. 2021 Dec;12(1):2583-2607. doi: 10.1080/21505594.2021.1980990.
8
Herpes Simplex Virus Evasion of Early Host Antiviral Responses.
Front Cell Infect Microbiol. 2019 Apr 30;9:127. doi: 10.3389/fcimb.2019.00127. eCollection 2019.
9
[Immune evasion by herpes simplex viruses].
Rev Chilena Infectol. 2015 Feb;32(1):58-70. doi: 10.4067/S0716-10182015000200013.
10
Innate Immune Mechanisms and Herpes Simplex Virus Infection and Disease.
Adv Anat Embryol Cell Biol. 2017;223:49-75. doi: 10.1007/978-3-319-53168-7_3.

引用本文的文献

1
Tackling cutaneous herpes simplex virus disease with topical immunomodulators-a call to action.
Clin Microbiol Rev. 2025 Mar 13;38(1):e0014724. doi: 10.1128/cmr.00147-24. Epub 2025 Feb 21.
2
A review of HSV pathogenesis, vaccine development, and advanced applications.
Mol Biomed. 2024 Aug 29;5(1):35. doi: 10.1186/s43556-024-00199-7.
5
The Effect of Electrical Stimulation Therapy on Brain Derived Neurotrophic Factor in Patients with Tinnitus.
Indian J Otolaryngol Head Neck Surg. 2023 Apr;75(Suppl 1):498-501. doi: 10.1007/s12070-022-03417-2. Epub 2023 Feb 28.
6
Blue light irradiation exerts anti-viral and anti-inflammatory properties against herpes simplex virus type 1 infection.
J Photochem Photobiol B. 2023 Feb;239:112632. doi: 10.1016/j.jphotobiol.2022.112632. Epub 2022 Dec 22.
7
Characterization of the Immunologic Phenotype of Dendritic Cells Infected With Herpes Simplex Virus 1.
Front Immunol. 2022 Jul 5;13:931740. doi: 10.3389/fimmu.2022.931740. eCollection 2022.
9
Herpes simplex virus interference with immunity: Focus on dendritic cells.
Virulence. 2021 Dec;12(1):2583-2607. doi: 10.1080/21505594.2021.1980990.

本文引用的文献

1
[Immune evasion by herpes simplex viruses].
Rev Chilena Infectol. 2015 Feb;32(1):58-70. doi: 10.4067/S0716-10182015000200013.
3
Direct activation of RIP3/MLKL-dependent necrosis by herpes simplex virus 1 (HSV-1) protein ICP6 triggers host antiviral defense.
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15438-43. doi: 10.1073/pnas.1412767111. Epub 2014 Oct 14.
4
Human herpesviruses-encoded dUTPases: a family of proteins that modulate dendritic cell function and innate immunity.
Front Microbiol. 2014 Sep 26;5:504. doi: 10.3389/fmicb.2014.00504. eCollection 2014.
5
Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease.
Med Microbiol Immunol. 2015 Apr;204(2):161-76. doi: 10.1007/s00430-014-0358-x. Epub 2014 Sep 11.
6
Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans.
J Virol. 2014 Nov;88(21):12612-22. doi: 10.1128/JVI.01930-14. Epub 2014 Aug 20.
9
Oligonucleotides designed to inhibit TLR9 block Herpes simplex virus type 1 infection at multiple steps.
Antiviral Res. 2014 Sep;109:83-96. doi: 10.1016/j.antiviral.2014.06.015. Epub 2014 Jul 1.
10
Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines?
Expert Rev Vaccines. 2014 Jun;13(6):691-710. doi: 10.1586/14760584.2014.910121.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验